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The development of imitinab has led to a revolution in the management of gastrointestinal stromal tumors (GIST), but surgical resection
remains the cornerstone of treatment for patients with localized disease. The principles to surgical treatment of GIST include careful handling
of tissues to prevent tumor rupture and resection to negative margins without the need for wide excision. Minimally invasive techniques have
proven equally efﬁcacious provided appropriate oncologic resections are performed.
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INTRODUCTION
Gastrointestinal stromal tumors (GIST) only comprise a small
minority of all gastrointestinal malignancies. Though they represent
the most common mesenchymal tumor of the GI tract, there are only
5,000–6,000 new cases per year in the United States [1]. Over the
past decade, GIST have become the paradigm of targeted molecular
therapy. Historically, these rare tumors were variously classiﬁed as
leiomyosarcoma or leiomyoblastoma, leiomyomas, or GI autonomic
nerve tumors. Cytotoxic chemotherapeutics were ineffective in con-
trolling disease and resection was the only effective treatment for
GIST. Metastatic and recurrent disease were commonly seen and, in
those scenarios, survival was poor. The identiﬁcation of a mutation
in the juxtamembrane domain of the c-kit receptor kinase in up to
90% of tumors has led to widespread application of imitinab mesy-
late, a small molecule capable of occupying the ATP binding site of
tyrosine kinase thereby inhibiting phosphorylation of downstream
signaling motifs.
While improved diagnostics and the development of effective
small molecule inhibitors, which inhibit the KIT proto-oncogene
mutations have led to revolution in the diagnosis and management of
GIST, resection remains the cornerstone of treatment for patients
with localized disease. Imitinab is the ﬁrst line therapy for metastatic
and recurrent GIST and can often be used in conjunction with surgi-
cal resection to produce long-term survival. A multidisciplinary
approach to the management of GIST combines radiologic, endo-
scopic, pathologic evaluations, and treatment with resection and
targeted therapy with tyrosine kinase inhibitors (TKI) [2].
SURGICALTREATMENT Of PRIMARY GIST
Diagnostic Considerations
Patients with GIST can present with a variety of symptoms dic-
tated primarily by their size and location at diagnosis. Small lesions
are often found incidentally during endoscopy or laparotomy for ot-
her indications. GIST generally produce symptoms from mass effect
though may be the source of signiﬁcant GI bleeding. Larger tumors
tend to be more symptomatic though small tumors are also associ-
ated with nausea, pain, early satiety, and bleeding (Figure 1). GIST
may ulcerate in to the GI lumen, resulting in subclinical bleeding
with microcytic anemia as a presenting symptom or in some cases,
causing signiﬁcant hematochezia. If tumors are particularly large,
abdominal distention or a palpable mass may be noted. GIST
occurring in or near narrow regions of the GI tract, such as the gas-
troesophageal junction or the pylorus may present with obstruction
[3].
Initial workup should include a thorough physical exam and
detailed history followed by cross sectional imaging using computed
tomography to both assess the extent of the primary tumor and
evaluate potential sites of metastatic disease, most commonly the
liver, omentum, or peritoneum. The origin of the tumor is typically
within the muscularis propria, so focal mural thickening can be seen
at the site of origin. Lymphatic metastases are rare and unlike other
sarcomas, spread to lung is uncommon. Features on magnetic reson-
ance imaging can be helpful for diagnosis. GIST typically enhance
with gadolinium contrast administration and are noted to have low
signal intensity on T1-weighted images and high signal intensity on
T2-weighted images. 18Flourodeoxyglucose positron emission tomo-
graphy (FDG-PET) can be used to evaluate GIST since the tumors
tend to be FDG avid. While PET can detect and characterize suspi-
cious distant lesions, its more common use is in evaluating response
to TKI therapy. PET before or after resection is not routinely used.
Endoscopic ultrasound can be helpful in better localizing tumors and
establishing a diagnosis, often by ultrasonographic conﬁrmation of
intramural tumor origin.
Because tumors are fragile and often hypervascular, biopsy is not
routinely recommended for diagnosis due to risk of capsular perfor-
ation, intraperitoneal seeding of tumor cells, and bleeding. While
endoscopically- or radiologically-guided biopsies can be performed
accurately, the submucosal location of many tumors often preclude
accurate sampling. Often, GIST have necrotic centers, limiting the
diagnostic utility of ﬁne needle aspirates or even core needle biopsies
[4]. However, biopsies may be helpful in select cases such as when
there is diagnostic uncertainty such as cases in which lymphoma or
other processes are a diagnostic consideration, or when location
prompts suspicion for other sarcoma subtypes (Figure 2) and situ-
ations where tumors are marginally resectable or primarily unresect-
able [5].
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Principles of Surgical Treatment
Once a diagnosis of GIST is conﬁrmed and metastatic disease
excluded, an operative strategy is formulated based on the size and
location of the tumor [6]. Controversy exists regarding treatment of
small lesions (<2 cm) incidentally identiﬁed during endoscopy, cross
sectional imaging, or surgical exploration for other indications. Most
would agree that a small tumor found at the time of laparotomy or
laparoscopy should be removed if in a location that would not cause
undo morbidity. When GISTs are identiﬁed during routine endos-
copy, decision-making may be more difﬁcult due to the lack of data
regarding growth rate and metastatic potential of small tumors.
Endoscopic features are unable to predict tumor behavior. In a recent
series of 23 patients found to have small GIST on routine endoscopy,
only three had increase in size of their lesion on follow-up exam [7].
These patients underwent subsequent surgical resection without evi-
dence of metastatic spread. Although sufﬁcient data on management
of small incidentally discovered GIST are lacking, a reasonable
strategy can include surveillance in 6–12 months. For lesions
>2 cm, surgical resection is the principle treatment and provides the
only means for cure.
At time of operation, care should be taken to thoroughly evaluate
the abdomen for metastatic disease paying particular attention to the
liver and peritoneum, the most common sites of disease spread. Per-
itoneal disease is often missed on preoperative imaging and suspi-
cious lesions should be resected if possible or biopsied to stage the
patient if too extensive for complete resection. Intraoperatively, care
should be taken when handling the lesion to ensure rupture does not
occur and the tumor pseudocapsule stays intact. This prevents exces-
sive bleeding and peritoneal dissemination of tumor cells. Unlike
adenocarcinomas which tend to inﬁltrate surround tissue, GISTs
have an extraluminal and exophytic growth pattern often with a
narrow base of attachment. Because of this, surgical resection to
microscopically clear margins is often easily achieved with minimal
removal of uninvolved tissue. As with other sarcomas, GISTs tend
not to invade surrounding structures, but rather displace them. Some
tumors often lift away from surrounding structures without the need
for extended resection. This often means favoring a segmental as
opposed to an anatomic resection.
Other tumors may become densely adherent to neighboring
organs such as the liver or spleen. In these instances, en bloc resec-
tion is preferred to prevent capsular disruption. In some cases, there
is both intra- and extra-luminal extension of tumor, requiring more a
more extensive resection for clearance of disease. Formal lymphade-
nectomy is not required. If enlarged nodes are found at the time of
resection, these should be resected with the primary lesion.
Esophagus
GISTs of the esophagus are quite rare comprising <5% of the
overall incidence [8]. Because of this, little data exists regarding
the appropriate management of these lesions. Often confused for the
more common leiomyomas, esophageal GISTs present with dyspha-
gia or bleeding. Indistinguishable on endoscopy and swallow study,
these lesions require biopsy and proper immunohistochemical stain-
ing prior to surgical intervention. Open or thoracoscopic enucleation
remains the treatment of choice for bengin leimyomas, but this is not
sufﬁcient for the treatment of GIST. Enucleation often leaves behind
a tumor laden pseudocapsule contributing to local recurrence. Strat-
egies for resection vary with location and more importantly size of
the tumor. Small lesions (< 2cm) can occasionally be treated with a
transmural wide excision and repair, assuming an R0 margin is
possible [9]. In a series of four patients, Blum et al. [10] report local
resection of esophageal GIST with primary closure of the defect. At
a median follow-up of 3 years, two patients had recurrent disease,
one distant and one at the resection site. The latter was treated with
an esophagectomy and remained disease free at follow-up. Care must
be taken not to narrow the esophageal lumen which can result in a
poor long-term outcome. For larger lesions, especially those located
near the GE junction, a formal esophagectomy with either an intra-
thoracic or cervical esophago-gastrostomy is needed [11]. In patients
with large tumors, neoadjuvant imitinab mesylate should be con-
sidered to decrease tumor size and improve the probability of a satis-
factory resection.
Fig. 1. This is a case of a 64-year old man who presented with
massive hematemesis, tachycardia, hypotension, and severe anemia.
He required massive transfusion and was found to have a submucosal
mass with spurting bleeding in the gastric fundus. He underwent
emergent resection of the mass with wedge gastrectomy for a histo-
logically benign spindle cell gastrointestinal stromal tumor measur-
ing 3.8 cm in size. [Color ﬁgure can be viewed in the online issue,
available at wileyonlinelibrary.com.]
Fig. 2. Cross-sectional imaging demonstrates an 18  11 cm mass
nearly encasing the IVC and aorta, with central low attenuation fea-
tures and gas. Differential diagnosis included leiomyosarcoma of the
IVC though biopsy conﬁrmed a diagnosis of gastrointestinal stromal
tumor.
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Stomach
The stomach is the most common site for GISTs with gastric
tumors comprising 70% of the overall incidence. Patients often
present with GI bleeding, but can also present with gastric obstruc-
tion when tumors become large or occur near the gastro-esophageal
junction or pylorus. They are best worked up with upper endoscopy
with endoscopic ultrasound to conﬁrm intramural origin. Biopsy is
not required to make the diagnosis of GIST. Small tumors are
occasionally found during endoscopy for other indications such as
GERD or ulcer disease. Gastric tumors tend to be more indolent than
those in the intestine or esophagus with smaller tumors rarely lead-
ing to metastatic disease or death [12]. When matched by size and
mitotic rate, non-gastric location is an independent poor prognostic
factor [13]. In a series of 1765 patients, the overall tumor speciﬁc
mortality was 17% and only 2% for patients with tumors <10 cm.
Resection strategy for gastric GIST depends primarily on the
location of the lesion within the stomach. As with all GISTs, the
operative goal is segmental resection with clear margins while limit-
ing potential tumor rupture by violating the tumor pseudocapsule.
Lesions located on the greater curve can most often be managed with
a wedge or sleeve-type resection. After inspection for metastatic dis-
ease, the short gastric vessels are divided separating the stomach
from the spleen. An area proximal and distal to the tumor is then
identiﬁed and resection performed using a stapler. Care must be
taken not to signiﬁcantly narrow the stomach leading to a functional
obstruction. This may be more common with large lesions and those
located at the incisura angularis along the lesser curve though wedge
resections can still be performed depending on anatomic contraints.
Antral lesions pose a similar problem as wedge resection can result
in gastric outﬂow obstruction. Unless the tumor is small, most would
advocate a distal gastrectomy with gastrojejunal or gastroduodenal
reconstruction.
Proximal lesions on the lesser curve or close proximity to the GE
junction may also be difﬁcult to treat, especially if there is a fairly
broad base of origin. Small lesions may be excised with closure of
the resultant defect ensuring the gastric inﬂow is not compromised
[14]. Even tumors near the GE junction can be handled with local
resections (Figure 3). For larger tumors, subtotal gastrectomy may
be required to remove the tumor. Despite some technical challenges,
an R0 resection is possible in a majority of cases [15,16].
Unlike adenocarcinoma, omentectomy or extended lymphadenec-
tomy is not required unless obviously involved with disease.
Occasionally, large tumors can become adherent to adjacent struc-
tures, requiring en bloc omentectomy, splenectomy, or distal pan-
createctomy to ensure capsule integrity. In a single institution review
of 37 patients undergoing resection of large (>10 cm) GISTs, 51%
of patients required removal of adjacent organs [17]. These patients
had a longer operative time and tended to have a poorer overall
prognosis.
Duodenum
Although the small intestine represents the second most common
site for GIST, duodenal origin remains rare at less <5% the overall
incidence [18]. While a majority of patients present with bleeding,
large tumors can lead to GI or pancreatico/biliary obstruction. The
best modality for diagnosis is endoscopy, but this can prove difﬁcult
for obstructing lesions, or those occurring in the distal duodenum
(D4). Similar to gastric GIST, the resection strategy depends on size
and location of the primary tumor as well as distance from the
ampulla. Small tumors in D1 or D2 that do not directly involve the
ampulla can be treated with wide excision and primary closure with
satisfactory results [18,19]. Lesions in D3 or D4 are best treated with
segmental resection with restoration of GI continuity via a duodeno-
jejunostomy. For large duodenal tumors or those close to or involv-
ing the ampulla, a pancreaticoduodenectomy is often needed for
complete resection. In a large series of duodenal GISTs reported by
Mitettinen et al. [18], 156 tumors were treated with enucleation
(n ¼ 15), wide excision (n ¼ 21), segmental resection (n ¼ 48), and
pancreaticoduodenectomy (n ¼ 21). Unfortunately, data was not pre-
sented on the adequacy of resection or recurrence rate by type of
resection. Yang et al. [20] reported a series of 21 patients undergoing
local resection (n ¼ 12) or pancreaticoduodencetomy (n ¼ 9). All
patients were resected to negative microscopic margins and only one
experienced recurrent disease. Although limited data exists, there
have been reports of neoadjuvant treatment with imatinib mesylate
leading to reduction in tumor size allowing for a more limited duo-
denal resection [14].
Jejunum and Ileum
The small intestine is the second most common location for
GISTs, comprising 20% of the overall incidence [21]. As with duo-
denal GISTs, GI bleeding is the most common presenting symptom
followed by obstruction [22]. Diagnosis can be difﬁcult, but visual-
ization of the lesion is often possible via push endoscopy or video
capsule endoscopy [23]. The former is the preferred technique as
biopsy is not possible when the capsule is used and entrapment of
the device has been reported [24]. In the largest published series of
906 small intestinal GISTs collected at the Armed Forces Institute of
Pathology, there was a higher proportion of lesions found in the jeju-
num than the ileum [22]. A majority of patients in that series (64%)
presented with tumors over 5 cm with 28% measuring >10 cm. The
same surgical principles of negative margins and prevention of tumor
rupture apply to intestinal GISTs. This is best accomplished by seg-
mental small bowel resection with primary anastomosis. Proximal
jejunal lesions near the root of the mesentery occasionally require
segmental resection with a duodenal-jejunal anastomosis [14].
Multiple studies have concluded that small intestinal GISTs are more
Fig. 3. Cross-sectional imaging with oral contrast demonstrates a
3.9  3.3 cm well-demarcated mass at the gastroesophageal junc-
tion/proximal cardia with protrusion into the gastric lumen. Wedge
gastrectomy with modiﬁed Nissen fundoplication was used to
accomplish complete resection of this GIST.
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malignant than those found in the stomach. They tend to present
with a larger size [12] and more mitotic bodies [22]. Irrespective of
these two important factors, small intestinal location is associated
with a poorer prognosis [25]. In a large study from Memorial Sloan
Kettering Cancer Center of 127 patients with GISTs, intestinal
location was an independent predictor of recurrence (HR 3.3, when
gastric location was used as a reference) [26].
Colon and Rectum
Due to its rare occurrence (<5% of overall incidence), little data
exists regarding the presentation and management of GISTs occur-
ring in the colon and rectum. The most common presenting symptom
is bleeding, with a near equal number of patients presenting with
abdominal pain [27]. Obstruction occurs less often than in other GI
locations due to the relatively large luminal diameter. Because a
large number of patients present with pain as their only symptom,
diagnosis is often made using cross sectional imaging. If conﬁr-
mation of location or a tissue biopsy is needed, colonoscopy should
be performed. A study of 17 patients in Taiwan reported a higher
incidence of distal lesions with 58% arising from the rectum and
only 18% in the ascending colon [27]. Colonic GISTs can typically
be treated with segmental resection and primary anastomosis. Unlike
colonic adenocarcinoma, formal lymphadenectomy is not needed,
unless obvious nodal involvement is identiﬁed.
Resection of rectal GISTs is more difﬁcult and is often associated
with greater morbidity. They often present with a bleeding and peri-
neal pain and are often large in size. Because of the conﬁned space
of the pelvis, tumors are often densely adherent to the pelvic ﬂoor
musculature making R0 resection challenging. If tumors can be freed
from surrounding tissues and sufﬁcient distance from the anal sphinc-
ter exists, a low resection if end to end anastomosis is possible. A
formal mesorectal excision is unnecessary and often leads to increased
morbidity by damaging the autonomic nerves. For lesions in the lower
rectum, and abdominoperineal resection is often needed. If the tumor
is unable to be separated from pelvic structures, a pelvic exenteration
is undertaken. Despite aggressive surgical approaches, the rate of
positive margins in rectal GISTs approaches 40%.
LAPAROSCOPY
In the past 10 years, laparoscopic approaches to GIST have
gained popularity due the technical ability to perform complete
resections in a minimally invasive fashion. With appropriate handling
of the tumor, laparoscopic approaches are safe and effective in
selected cases. Although no randomized trials comparing open versus
laparoscopically resected tumors exist, reports from multiple small
series highlight the safety and feasibility of this approach [2].
Novitsky et al. [28] reported on 50 consecutive patients undergoing
laparoscopic resection of GISTs. There were no instances of conver-
sion to open procedure and 96% of patients remained tumor free at
36 months. In a similar study, Lai et al. [29] reported on 28 patients
with gastric GISTs undergoing minimally invasive resection. At a
mean follow-up of 43 months, there were no documented recur-
rences. It is important to follow the same surgical principles of lapa-
rotomy when performing laparoscopic GIST resections.
Tumor manipulation should be minimized to reduce the risk of
rupture and tumor spread. All specimens should be removed in pro-
tective bags or pouches to prevent unintended rupture and port site
seeding. There should be little hesitation to convert to an open tech-
nique if failure to do so will result in unsatisfactory oncologic out-
come or untoward outcome for the patient. Some have advocated a
hand assisted technique when dealing with larger tumors (>5 cm) or
when adherence to surrounding structures is encountered [30].
Neoadjuvant Therapy
The role of preoperative imatinib in the treatment of GIST
remains unknown. In many patients with large tumors located in
difﬁcult to resect areas, neoadjuvant imatinib can lead to reduction
in tumor size making surgical resection both feasible and safe
(Figure 4). Furthermore, the risk of tumor rupture during surgical
manipulation is reduced after a signiﬁcant tumor response. In a study
of 36 patients with difﬁcult to resect tumors, preoperative adminis-
tration of imatinib resulted improved ability to completely excise
tumors with substantially decreased need for removal of surrounding
organs [31]. In a second smaller study by Fiore et al.[32], 15 patients
with extensive tumor burden or high perioperative risk underwent
Fig. 4. CT imaging (4a) shows a large gastrointestinal stromal
tumor measuring 11.5  7.4  10 centimeters along the lesser cur-
vature of her stomach. This extended to the left lobe of the liver and
the body and tail of the pancreas. The patient was initiated on neo-
adjuvant imatinib and dramatic radiologic improvement in GIST
tumor size was seen. After stability in interval CT scan (4b), the
patient underwent exploration and wedge resection of the lesser cur-
vature of the stomach. The tumor was easily separated from sur-
rounding organs.
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neoadjuvant therapy with imatinib prior to surgical resection. At a
mean time of 9 months, all patients demonstrated reduction in tumor
size and were able to undergo a more limited resection. Although
the sample sizes in these reports are small and prone to recall biases
in terms of type of operation performed, they do demonstrate the
potential utility of this approach in high-risk patients and tumors.
The only multicenter trial investigating the use of neoadjuvant
imatinib is the Radiation Therapy Oncology Group (RTOG) 0312. In
this trial, patients with primary resectable or recurrent tumors were
given 600 mg of imatinib for 8–12 weeks prior to surgery. Patients
who experienced objective response or disease stability were eligible
for surgical resection followed by 2 years of adjuvant therapy. When
compared with historical controls, 2-year disease-free survival was
superior in the patients treated with neoadjuvant therapy. Contro-
versy remains regarding the optimal duration of neoadjuvant therapy.
Most agree that surgical resection should occur when TKI induced
regression plateaus, which typically occurs at 6–9 months after
initiation. Patients should be followed with serial CT scans every
3 months to assess continued tumor size reduction. Surgical interven-
tion should occur after stable disease is noted on two consecutive
scans. If it remains unclear whether imitinab is having a biologic
effect, PET scans can be helpful by documenting decrease or cessa-
tion of tumor activity [33]. If tumors display no size reduction, but
become PET negative, most would consider surgical intervention.
This highlights a unique difference between GIST and other solid
organ malignancies.
While response to chemotherapy or radiation is typically
measured by reduction is tumor size such as the Response Evaluation
Criteria In Solid Tumors or RECIST, this can be misleading in eval-
uating response to imatinib. The best method for documenting the
efﬁcacy of TKIs is in cessation of biologic activity, not reduction in
size. Because of this, Choi et al. [34] suggested a new method for
documenting response to therapy using not only reduction in tumor
size, but changes in tumor density as measured by CT scan. They
found that when tumors demonstrated at least a 10% reduction in
size or a 15% decrease in density, there was near 100% correlation
with decrease in activity determined by PET scan. Many have
adopted these new criteria for evaluating response to therapy. If
tumors fail to show response to up front imatinib, second and third
line TKIs may be used prior to intervention.
Current NCCN guidelines recommend neoadjuvant therapy for
patients with large tumors where resection would cause undo mor-
bidity or functional deﬁcit, and small tumors in difﬁcult to treat areas
such as the GE junction or low rectum. The use of neoadjuvant ima-
tinib should be decided on a case by case basis at centers with
experience in the treatment of GIST [35].
SURGICALTREATMENT OF METASTATIC
DISEASE
The principal therapy for patients with metastatic GIST is imatinib.
It can lead to tumor regression or stability and has dramatically
lengthened survival with this disease. Unfortunately, the development
of resistance to this therapy is common with 50% of patients experi-
encing tumor growth at 2 years. Because of this, if the opportunity
exists to resect all visible disease, it should be taken. This usually
involves anatomic or non-anatomic hepatic resections as well as
removal of peritoneal deposits. In three recent series reporting results
of cytoreductive surgery, gross tumor removal was achieved in 80% of
patients with 50% of patients deemed microscopically disease free
[14]. The timing of surgery remains controversial, but most agree that
is should occur at the time of maximal tumor response, but before
resistance can develop. A widely accepted strategy is to document
cessation of tumor regression on consecutive CAT scans prior to
operative intervention. This typically occurs 6–9 months into therapy.
A second indication for resection of metastatic GIST is in the
setting of resistance formation. Because survival in patients depends
on imitinab mediated disease stability, resection of tumor deposits
that develop resistance to chemotherapy and begin to grow makes
oncologic sense. There are two types of disease progression of tyro-
sine kinase blocking therapy. The ﬁrst is localized progression where
isolated growth of limited numbers of metastatic deposits is seen
(Figure 5). The second is diffuse progression where multiple or all
lesions show growth. DeMatteo et al. [36], reported that while
patients with stable disease of localized progression beneﬁt from
operative debulking, there is little improvement in overall survival
for patients with diffuse progression.
Timing and treatment of patients with metastatic GIST requires
experience and expertise necessitating referral of these patients to
Fig. 5. This is a case of a 71-year old woman diagnosed with meta-
static GIST (small bowel primary and innumerable synchronous liver
metastases). Disease was stable on imatinib for 3 years (5a), but she
was then noted to have lower GI bleeding and progression of disease
at the primary site though all the liver lesions were stable (5b). She
did not tolerate increased imatinib dosing and second-line sunitinib.
With an ongoing transfusion requirement, she underwent resection of
a single progressive site of disease with small bowel resection.
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appropriate tertiary care centers. Speciﬁc considerations for surgical
treatment of recurrent disease are covered extensively elsewhere and
are outside the scope of this review.
SUMMARY
Even with the availability of an effective molecularly targeted
agent, the primary treatment modality for localized GIST is surgical
resection. Tenets of surgical resection include complete micro-
scopic resection with organ-preserving approaches when possible.
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